6972172818 18:18 Fron: PY Woodson C. Merrell M Webfax Page: 6713 LabCorp Patient Report Patient: EPSTEIN, JEFFREY Specimen ID: 257-480-2371-0 Date collected: 09/14/2018 1255 Local DOB: 01/20/1953 Patient ID: Control ID: F5831143092 Lipoprotein (a) 20 Note: nmol/L <75 Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ng/mL 49 - 188 Negative umol/L 0.0 - 15.0 Low ng/mL 4.0 - 15.2 ng/dL 0.82 - 1.77 ug/dL Cortisol AM 6.2 - 19.4 Cortisol PM 2.3 - 11.9 ug/dL 30.9 - 295.6 pg/mL 7.6 ~ 42.6 mg/dL S37] 026 Therapeutic target for gout patients: <6.0 ethnicities. IGFr-1 Insulin-Like Growth Factor I 137 ANA w/Reflex ANA Direct Negative Homocyst(¢e)ine, Plasma 14.9 Prolactin 3.9 Thyroxine (T4) Free, Direct, § T4, Pree (Direct) 1.05 Cortisol 3.7 DHEA-Sulfate 181.8 Estradiol 28.3 Roche ECLIA methodology Uric Acid Uric Acid 6.8 Please Note: Phosphorus 3.6 LDE 213 GGT 25 Amylase 37 Ferritin, Serum 104 Insulin 47.2 ng/dL 2.5 - 4.5 Iu/L 121 - 224 Iu/L 0 - 65 U/L 31 - 124 ng/mL 30 - 400 High ulU/mL 2.6 - 24.9 01 02 61 01 01 o1 01 01 01 01 01 ol Date issued: 09/20/18 0832 ET FINAL REPORT Page Sof 6 M you have receives this document in erot, please cal © 1995-2018 Laboratory Corporation af America® Hokfings Aa Fugit Reserved - Enterprise Report Version: 1.00 EFTA00314057